Tarsons Products Limited , a leading plastic labware manufacturer in India, has reported a mixed set of financial results for the second quarter of fiscal year 2026. The company saw revenue growth but experienced a decline in profits due to higher depreciation expenses associated with its ongoing capacity expansion.

Financial Highlights

• Revenue for Q2 FY26 stood at INR 81.00 crores, showing growth from the previous year.
• EBITDA rose by 11% year-on-year to INR 26.00 crores, with the EBITDA margin improving to 32.50% from 29.30% in Q2 FY25.
• Profit After Tax (PAT) declined to INR 6.50 crores from INR 12.90 crores in the same quarter last year.

Key Factors Affecting Performance

The decline in profitability is primarily attributed to higher depreciation expenses of INR 20.00 crores arising from the partial capitalization of the Panchla facility. The company expects PAT margins to normalize once the facility is fully commissioned and begins contributing to revenue.

Capacity Expansion Update

Tarsons is nearing completion of its planned capex at the Panchla and Amta facilities, which are expected to be fully operational by Q4 FY26. The expansion aims to:

• Significantly enhance the company's addressable market
• Enable deeper penetration within existing customer base
• Help acquire new customers across diverse industries

The company anticipates a strong turnaround in both revenue and profitability as utilization levels ramp up through FY27 and FY28.

Product Portfolio and Market Outlook

Tarsons has launched several new products, including:

• Bioprocess-related products like PET and PETG bottles
• Roller bottles
• Upcoming cell culture products

The company remains optimistic about growth opportunities in both domestic and export markets, citing:

• Increasing adoption of high-quality labware consumables
• Growing investments in life science and research

Challenges and Strategies

While facing competitive pressures in the domestic market, Tarsons is focusing on:

1. Launching new products to increase wallet share with existing customers
2. Expanding its presence in export markets
3. Enhancing operational efficiency and automation across manufacturing processes

Management Commentary

Santosh Agarwal, CFO of Tarsons Products Limited, stated, "Our sustained performance in the face of sectoral challenges showcases the resilience of our business model, the superior quality of our products, and the enduring trust that Tarsons as a brand enjoys within the life science industry."

The management expects the new capacity to generate peak revenue potential of INR 350.00-400.00 crores over the next 3-5 years, with about INR 100.00-125.00 crores coming from capacity expansion of existing products and the remainder from new product lines.

Conclusion

While Tarsons Products faces short-term challenges due to increased depreciation and competitive pressures, the company's expansion strategy and focus on new product development position it for potential growth in the coming years. Investors and stakeholders will be watching closely to see how quickly the new capacity translates into revenue and profitability improvements.

Tarsons Products Limited , a leading Indian labware manufacturer, has reported a mixed financial performance for the first half of fiscal year 2026 (H1FY26). The company's results showcase revenue growth amidst challenges in profitability.

Key Financial Highlights

• Revenue Growth: Tarsons Products reported consolidated revenue of Rs 193.70 crore for H1FY26, reflecting a 5.2% year-on-year growth.
• EBITDA Performance: EBITDA grew by 18.4% to Rs 52.10 crore compared to Rs 44.00 crore in H1FY25.
• Profit After Tax: The company experienced a significant decline in profit after tax, primarily due to accelerated depreciation and higher finance costs associated with the capitalization of its new facility at Panchla.
• Cash PAT: Cash PAT for H1FY26 stood at Rs 47.50 crore, representing a 20.8% year-on-year growth.

Operational Insights

Tarsons Products, with over 40 years of experience in the industry, offers more than 2,000 SKUs across 350 product segments. The company's management anticipates revenue contribution from the new Panchla facility to commence in the coming years, with expectations of swift ramp-up from FY27 onwards.

Management Commentary

Mr. Aryan Sehgal, Promoter and Whole-time Director of Tarsons, commented on the performance: "With expanded capacities and the addition of new products, we expect to significantly increase our addressable market, driving sustained revenue growth in the years ahead. Backed by decades of experience in the plastic labware industry and the strong brand equity of Tarsons, we remain confident of a swift ramp-up of the new facilities from FY27 onwards, contributing meaningfully to overall revenue growth and margin expansion through operating leverage."

Financial Performance Breakdown

Future Outlook

Despite the current challenges, Tarsons Products remains committed to long-term growth prospects. The company continues to invest through the current down cycle to strengthen its capacities and capabilities, positioning itself for sustainable growth over the next three to five years.

The management's focus on expanding capacities, introducing new products, and leveraging its strong brand equity suggests a strategic approach to overcoming short-term hurdles and capitalizing on future market opportunities.

Conclusion

While Tarsons Products has demonstrated resilience in revenue growth and operational performance, the impact of accelerated depreciation and higher finance costs on profitability highlights the challenges associated with expansion and new facility investments. The company's strong cash PAT growth and management's confidence in future ramp-up indicate potential for improved performance in the coming years, particularly as new facilities begin contributing to revenue.